Core Viewpoint - Hims & Hers Health, Inc. is facing securities class action lawsuits due to allegations of failing to disclose material information during the class period, which has led to a significant drop in share price following a partnership termination announcement by Novo Nordisk [3][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to file lead plaintiff applications in the securities class action lawsuits against Hims, specifically for those who purchased securities between April 29, 2025, and June 23, 2025 [1]. - The lawsuits are pending in the United States District Court for the Northern District of California, with the first case being Sookdeo v. Hims & Hers Health, Inc. and a subsequent case expanding the class period [5]. Group 2: Company Impact - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims, citing violations of laws regarding the sale of compounded drugs and concerns over patient safety due to potentially unsafe ingredients in products sold by Hims [4]. - Following this announcement, Hims' share price fell by $22.24, or 34.6%, closing at $41.98 per share on unusually heavy trading volume [4].

Core Viewpoint - Compass Diversified Holdings is facing securities class action lawsuits due to alleged failure to disclose material information during the class period, leading to significant financial repercussions for investors [3][4]. Company Information - The lawsuits are related to the period from March 1, 2023, to May 7, 2025, and are pending in the United States District Court for the Central District of California [1]. - The company disclosed on May 7, 2025, that its financial statements for fiscal 2024 require restatement, which has raised concerns about its subsidiary, Lugano Holding, Inc. [4]. - Following the announcement, Compass' share price dropped approximately 62%, from $17.25 to $6.55 per share within a day [4]. Legal Context - The case Matthews v. Compass Group Diversified Holdings, Inc. is one of the lawsuits filed, with a subsequent case, Tan v. Compass Group Diversified Holdings, Inc., extending the class period [5]. - The allegations include violations of federal securities laws due to the company's failure to disclose material information [3]. Investor Information - ClaimsFiler is providing a service to help investors file lead plaintiff applications by the deadline of July 8, 2025 [1]. - Investors can access information and legal options through ClaimsFiler, which aims to assist retail investors in recovering funds from securities class action settlements [6].

Core Viewpoint - The Organon class action lawsuit alleges that the company and its executives made misleading statements regarding capital allocation and dividend payouts, leading to significant financial losses for investors [1][4]. Company Overview - Organon develops and delivers health solutions through prescription therapies and medical devices [3]. Allegations of the Lawsuit - The lawsuit claims that Organon concealed material information about its capital allocation priorities, particularly regarding the future of its quarterly dividend payout [4]. - It is alleged that Organon's reports on dividend payouts being a "number one priority" were misleading, as they were offset by a newly implemented debt reduction strategy, resulting in a more than 70% decrease in the quarterly dividend [4]. - Following the acquisition of Dermavant Sciences Ltd., Organon prioritized debt reduction, which further impacted its dividend strategy [4]. Financial Impact - On May 1, 2025, Organon reported first quarter 2025 financial results and announced a drastic reduction in its dividend payout from $0.28 to $0.02, causing its stock price to fall by over 27% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Organon securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Vestis Corporation (NYSE:VSTS) securities between May 2, 2024 and May 6, 2025. Vestis is a North American company that provides uniform rentals and workplace supplies across the U.S. and Canada. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins LLP is Investigati ...

SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired PepGen Inc. (NASDAQ:PEPG) securities between March 7, 2024 and March 3, 2025. PepGen is a clinical-stage biotechnology company that focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The Company’s lead product candidate was PGN-EDO51, a proprietary enhanced deliv ...

Core Viewpoint - A securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. due to allegations of misleading statements regarding the safety and efficacy of its treatment ELEVIDYS, which has been linked to severe adverse events including patient deaths [1][2]. Group 1: Allegations and Lawsuit Details - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, including severe side effects that were not detected during clinical trials [2]. - The class period for the lawsuit is defined as between June 22, 2023, and June 24, 2025, during which investors acquired Sarepta securities [1]. Group 2: Impact of Adverse Events on Stock Price - On March 18, 2025, Sarepta reported a patient death due to acute liver failure linked to ELEVIDYS, resulting in a stock price drop of over 27% [3]. - Following the announcement on April 4, 2025, regarding regulatory scrutiny and the halting of recruitment in some clinical studies, Sarepta's stock fell more than 7% [4]. - A second patient death was reported on June 15, 2025, leading to a suspension of ELEVIDYS shipments and a further stock decline of over 42% [5]. - The FDA issued a Safety Communication on June 24, 2025, regarding the investigation into acute liver failure cases, causing an additional stock drop of more than 8% [6]. Group 3: Investor Actions - Investors who purchased Sarepta shares are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline of August 25, 2025, to discuss their rights and interests in the class action [7].

NEW YORK, June 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Open Lending Corporation (NASDAQ: LPRO) between February 24, 2022 and March 31, 2025, both dates inclusive (the "Class Period"), of the important June 30, 2025 lead plaintiff deadline.So what: If you purchased Open Lending securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen ...

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Red Cat Holdings, Inc. (NASDAQ: RCAT) between March 18, 2022 and January 15, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Red Cat securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement ...

Core Viewpoint - Iovance Biotherapeutics Inc. is undergoing a leadership transition with the resignation of CFO Jean-Marc Bellemin amid commercial challenges and a class-action lawsuit related to its flagship drug Amtagvi [1][2][3]. Group 1: Leadership Transition - CFO Jean-Marc Bellemin will resign effective July 10, 2025, to pursue other endeavors, having held the position since November 2020 [1][2]. - The company has not yet named a successor for the CFO role, creating uncertainty during a challenging period [2]. Group 2: Commercial Challenges - Iovance's first-quarter sales for Amtagvi significantly underperformed expectations, leading to a revision of full-year revenue projections [3]. - The company attributed its disappointing results to "recent launch dynamics," including slow treatment timelines and higher-than-expected patient drop-off rates [6]. Group 3: Legal Issues - Iovance is facing a class-action lawsuit alleging securities fraud related to its portrayal of authorized treatment centers (ATCs) that are essential for administering Amtagvi [4][5]. - The lawsuit claims that the company misrepresented the operational efficiency of ATCs, which were reportedly experiencing delays and inefficiencies [5]. Group 4: Market Reaction - Following the disclosure of underwhelming first-quarter results and revised revenue guidance, Iovance's stock fell over 44%, from $3.17 to $1.75 per share within a day [7].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, alleging misleading statements and failures to disclose critical information regarding partnerships and product offerings [1][5]. Group 1: Lawsuit Details - The class action lawsuit pertains to common stock purchases of Hims & Hers Health, Inc. between April 29, 2025, and June 23, 2025 [1]. - The lawsuit claims that Hims made false and misleading statements about its collaboration with Novo Nordisk A/S, particularly regarding the availability of the weight-loss drug Wegovy and compounded semaglutide products [5]. - Investors are encouraged to join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked highly in securities class action settlements and has recovered hundreds of millions of dollars for investors [4].